Current Report Filing (8-k)
July 13 2020 - 8:01AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): July 10, 2020
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State or other jurisdiction
of
|
|
(Commission
|
|
(I.R.S. Employer
|
incorporation or
organization)
|
|
File Number)
|
|
Identification Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock, no
par value
|
|
AKER
|
|
The NASDAQ Capital
Market
|
Item
5.08 Shareholder Director Nominations
On
July 10, 2020, the board of directors (the “Board”) of Akers Biosciences, Inc. (the “Company”) established
August 27, 2020, as the date for the Company’s 2020 Annual Meeting of Stockholders (the “Annual Meeting”) and
set July 10, 2020, as the record date for the Annual Meeting. Due to the fact that the date of the Annual Meeting has been changed
by more than 30 days from the anniversary date of the 2019 Annual Meeting of Stockholders, the Company is providing the due date
for submission of any qualified stockholder proposal or qualified stockholder nominations.
In
accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the Company’s amended and restated bylaws, as amended (the “Bylaws”), the deadline for receipt of stockholder
proposals or nominations for inclusion in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8 will
be no later than 5:00 p.m., Eastern Time, July 23, 2020. Stockholder proposals must comply with all of the applicable requirements
set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act
and the Bylaws.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS BIOSCIENCES, INC.
|
|
|
Dated: July 13, 2020
|
/s/
Christopher C. Schreiber
|
|
Christopher C. Schreiber
|
|
Executive Chairman of the Board of Directors
and Director
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024